Enteric-Coated mTOR Inhibitors for Intestinal Polyp Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for preventing intestinal polyps and cancer are inadequate, particularly for patients at risk, as they are either ineffective, toxic, or have significant cardiovascular side effects, necessitating a safer and more effective chemopreventive approach.
Innovation Solution
Administering rapamycin or its analogs, optionally encapsulated or coated, to patients at risk for developing intestinal polyps or cancer, utilizing enteric coatings to enhance bioavailability and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If COX-2 inhibitors (celecoxib) are used for chemoprevention of intestinal polyps, then polyp development is reduced, but cardiovascular toxicity occurs
Solution Approach 1:
The patent changes the pharmacological parameter from COX-2 inhibition to mTOR inhibition, switching to a different molecular target and mechanism of action that achieves chemoprevention without cardiovascular toxicity. Rapamycin and its analogs inhibit mTOR signaling pathway, which is crucial for cell growth and proliferation, thereby preventing polyp development while avoiding the cardiovascular side effects associated with COX-2 inhibitors.
2Reliability
If non-selective NSAIDs (sulindac, naproxen) are used for chemoprevention, then polyp progression is delayed, but cardiovascular thrombotic events increase
Solution Approach 1:
The patent changes the mechanism of action from non-selective NSAID inhibition of COX-1 and COX-2 enzymes to specific mTOR inhibition. This parameter change in the pharmacological approach achieves polyp progression delay through a different pathway that does not interfere with platelet function or increase thrombotic risk, thereby avoiding cardiovascular thrombotic events.
3Reliability
If rapamycin is administered to prevent intestinal polyps, then polyp development is prevented and cancer conversion is inhibited, but gastrointestinal side effects may occur
Solution Approach 1:
The patent uses enteric coating as an intermediary delivery system for rapamycin. The enteric coating protects the drug from degradation in the stomach and controls its release in the intestine, thereby reducing gastrointestinal side effects while maintaining the therapeutic benefit of polyp prevention and cancer conversion inhibition.
4Reliability
If encapsulated or coated rapamycin is used, then bioavailability is enhanced and toxicity is reduced, but manufacturing complexity increases
Solution Approach 1:
The patent employs established enteric coating technologies and encapsulation methods that are well-documented in pharmaceutical manufacturing. By using standard coating materials and processes, the patent enhances bioavailability and reduces toxicity while minimizing the increase in manufacturing complexity through the application of conventional pharmaceutical engineering practices.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively prevents the development of intestinal polyps, reduces their severity, and inhibits the conversion to cancer, offering a well-tolerated and long-term solution for patients at risk, including those with Familial Adenomatous Polyposis (FAP).
Implementation Method 1
The methods and compositions include rapamycin, rapamycin analogs, or other inhibitors of the mammalian target of rapamycin ('mTOR' or 'mTORC1')
Implementation Method 2
Administering rapamycin or its analogs, optionally encapsulated or coated, to patients at risk for developing intestinal polyps or cancer, utilizing enteric coatings to enhance bioavailability and reduce toxicity
Data Source
AI summary
Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).